Improvement of methods for the treatment of the effusive form of feline infectious peritonitis

Feline infectious peritonitis (FIP) is a fatal immune-mediated pathology caused by a mutated feline coronavirus (FCoV). The wet (effusive) form of the disease is accompanied by the development of polyserositis, most commonly manifested as ascites, pleurisy, and pericarditis. Previously, FIP was untreatable and considered 100% fatal, particularly in the presence of neurological or ophthalmological lesions. The aim of the study was to improve treatment methods for the effusive form of feline infectious peritonitis. During 2023–2026, 120 cats suffering from the effusive form of FIP were examined at the "Vet Center" veterinary clinic (Irpin). A preliminary diagnosis was established based on epizootiological, clinical, hematological, ultrasonographic, and radiographic examinations, as well as ascites fluid analysis. The definitive diagnosis was confirmed by the "BALD" laboratory through the detection of the pathogen in ascites fluid using polymerase chain reaction (PCR) or in blood via enzyme-linked immunosorbent assay (ELISA). The diseased animals were divided into two groups: Protocol I (53 cats): standard treatment without the use of a probiotic. Protocol II (67 cats): comprehensive treatment with the additional use of the probiotic. The total duration of therapy in both groups was 84 days and consisted of two consecutive stages: First 42 days: subcutaneous administration of GS-441524 at a dose of 6–8 mg/kg once daily. Next 42 days: oral administration of Molnupiravir tablets at a dose of 15–18 mg/kg twice daily. To evaluate the efficacy of the proposed protocols, hematological and biochemical blood parameters were analyzed. For comparative analysis, age-matched groups (10 diseased cats in each) were selected prior to treatment and 14 days after its completion. Hematological studies were performed using a Micro-20 Plus automated analyzer, while the serum biochemical profile was determined using an HTI BioChem FC-120 automated biochemical analyzer (USA) with reagents from PZ Cormay S.A. (Poland). High therapeutic efficacy in the treatment of effusive FIP is achieved through the sequential administration of antiviral agents: parenterally with GS-441524 during the initial phase (for 42 days), followed by oral Molnupiravir in the final phase (for the subsequent 42 days). This regimen must be combined with intensive symptomatic and antibacterial therapy. The inclusion of "Embiotic" into the comprehensive protocol increases treatment efficacy by 6% and contributes to a statistically significant (P<0.05; P<0.01; P<0.001) normalization of key hematological and biochemical blood parameters to the level of clinically healthy animals as early as two weeks after the completion of the course.

Authors

Institutions

Publication Details

Journal
Науковий вісник Львівського національного університету ветеринарної медицини та біотехнологій імені С.З. Ґжицького
Published
2026-11-16
DOI
https://doi.org/10.32782/nvlvet12211
Primary Topic
Animal Virus Infections Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Improvement of methods for the treatment of the effusive form of feline infectious peritonitis

O. Ye. Galatiuk, S. P. Tkachyvskyi
4 links
Науковий вісник Львівського національного університету ветеринарної медицини та біотехнологій імені С.З. Ґжицького
Animal Virus Infections Studies
article

Improvement of methods for the treatment of the effusive form of feline infectious peritonitis

O. Ye. Galatiuk, S. P. Tkachyvskyi
article en

Abstract

Feline infectious peritonitis (FIP) is a fatal immune-mediated pathology caused by a mutated feline coronavirus (FCoV). The wet (effusive) form of the disease is accompanied by the development of polyserositis, most commonly manifested as ascites, pleurisy, and pericarditis. Previously, FIP was untreatable and considered 100% fatal, particularly in the presence of neurological or ophthalmological lesions. The aim of the study was to improve treatment methods for the effusive form of feline infectious peritonitis. During 2023–2026, 120 cats suffering from the effusive form of FIP were examined at the "Vet Center" veterinary clinic (Irpin). A preliminary diagnosis was established based on epizootiological, clinical, hematological, ultrasonographic, and radiographic examinations, as well as ascites fluid analysis. The definitive diagnosis was confirmed by the "BALD" laboratory through the detection of the pathogen in ascites fluid using polymerase chain reaction (PCR) or in blood via enzyme-linked immunosorbent assay (ELISA). The diseased animals were divided into two groups: Protocol I (53 cats): standard treatment without the use of a probiotic. Protocol II (67 cats): comprehensive treatment with the additional use of the probiotic. The total duration of therapy in both groups was 84 days and consisted of two consecutive stages: First 42 days: subcutaneous administration of GS-441524 at a dose of 6–8 mg/kg once daily. Next 42 days: oral administration of Molnupiravir tablets at a dose of 15–18 mg/kg twice daily. To evaluate the efficacy of the proposed protocols, hematological and biochemical blood parameters were analyzed. For comparative analysis, age-matched groups (10 diseased cats in each) were selected prior to treatment and 14 days after its completion. Hematological studies were performed using a Micro-20 Plus automated analyzer, while the serum biochemical profile was determined using an HTI BioChem FC-120 automated biochemical analyzer (USA) with reagents from PZ Cormay S.A. (Poland). High therapeutic efficacy in the treatment of effusive FIP is achieved through the sequential administration of antiviral agents: parenterally with GS-441524 during the initial phase (for 42 days), followed by oral Molnupiravir in the final phase (for the subsequent 42 days). This regimen must be combined with intensive symptomatic and antibacterial therapy. The inclusion of "Embiotic" into the comprehensive protocol increases treatment efficacy by 6% and contributes to a statistically significant (P<0.05; P<0.01; P<0.001) normalization of key hematological and biochemical blood parameters to the level of clinically healthy animals as early as two weeks after the completion of the course.

Науковий вісник Львівського національного університету ветеринарної медицини та біотехнологій імені С.З. ҐжицькогоVol. 28(122)
Polissia National University (UA)
Good health and well-being
Animal Virus Infections Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon